# EDGAR Filing Document

**Accession Number:** 0001129928
**File Stem:** 0001104659-26-038083
**Filing Date:** 2026-4
**Character Count:** 6544
**Document Hash:** 93f79c6da27c91cd89c484408d6b169d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-038083.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0001104659-26-038083

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260331

**EFFECTIVENESS DATE**: 20260401

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYTICS BIOTECH INC
- **CENTRAL INDEX KEY:** 0001129928
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-171625
- **FILM NUMBER:** 26824439

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 804, 322 - 11 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** A0
- **BUSINESS PHONE:** 4036707377

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 804, 322 - 11 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** A0

**As filed with the U.S. Securities and Exchange Commission on March 31, 2026.**

**Registration No. 333-171625**

**Registration No. 333-205708**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION <br> STATEMENT (333-171625)**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION <br> STATEMENT (333-205708)**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Oncolytics Biotech Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Nevada** | **98-0541667** |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |

---

**4350 Executive Drive, Suite 325**

**San Diego, California 92121**

(Address of principal executive offices) (Zip Code)

**Amended and Restated Stock Option Plan**

**Amended and Restated Incentive Share Award Plan**

(Full title of the plans)

**Jared Kelly**

**Chief Executive Officer**

**4350 Executive Drive, Suite 325**

**San Diego, California 92121**

**(403) 670-7377**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copy to:***

**Christopher J. Clark, Esq.**

**Latham & Watkins LLP**

**555 Eleventh Street N.W., Suite 1000**

**Washington, D.C. 20004**

**(202) 637-2200**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**DEREGISTRATION OF SECURITIES**

These post-effective amendments relate to the following Registration Statements on Form S-8 (collectively, the "Registration Statements") and are being filed to deregister all securities that were registered for issuance on the Registration Statements and remain unsold thereunder:

· Registration Statement on Form S-8 (File No. 333-171625) filed with the U.S. Securities and Exchange Commission (the "SEC") on [January 10, 2011](https://www.sec.gov/Archives/edgar/data/1129928/000091228211000007/oncolyticss8_012011.htm) ; and

· Registration Statement on Form S-8 (File No. 333-205708) filed with the SEC on [July 17, 2015](https://www.sec.gov/Archives/edgar/data/1129928/000091228215000245/oncolyticss8_071515.htm) .

On March 17, 2026, the Company completed the first step of its previously announced two-step redomestication by changing its jurisdiction of incorporation from the Province of Alberta, Canada, to the Province of British Columbia, Canada (the "Continuance"), pursuant to a "continuance" effected in accordance with Section 189 of the *Business Corporations Act (Alberta)* and a "continuation" in accordance with Section 303 of the *Business Corporations Act (British Columbia)* (the "BCBCA"). On March 31, 2026, the Company completed the second step of its redomestication by changing its jurisdiction of incorporation from the Province of British Columbia, Canada, to the State of Nevada in the United States pursuant to a "continuation out" effected in accordance with Section 308 of the BCBCA and a "domestication" under Nevada Revised Statutes 92A.270 (the "Domestication").

Upon effectiveness of the Continuance, each outstanding common share, no par value per share, of the Company (an Alberta corporation) at the time of the Continuance remained issued and outstanding as a common share, no par value per share, of the Company (a British Columbia corporation). Upon effectiveness of the Domestication, each outstanding common share of the Company (a British Columbia corporation) at the time of the Domestication automatically became one outstanding share of common stock, par value $0.001 per share, of the Company (a Nevada corporation) (the "Common Stock"). The Common Stock continues to be listed for trading on The Nasdaq Stock Market, LLC under the symbol "ONCY."

In connection with the Domestication, the Company adopted the Oncolytics Biotech Inc. 2026 Incentive Award Plan and terminated all offers and sales of its securities registered for issuance on the Registration Statements that remained unsold thereunder as of the date hereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing these post-effective amendments and has duly caused these post-effective amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 31st, 2026.

---

| | |
|:---|:---|
| **ONCOLYTICS BIOTECH INC.** | **ONCOLYTICS BIOTECH INC.** |
| By: | /s/ Jared Kelly |
|  | Jared Kelly |
|  | Chief Executive Officer |

---

No other person is required to sign these post-effective amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.